HOME PAGE Search this site: Yale University School of Medicine 333 Cedar Street New Haven, CT 06510 USA (203) 432-1333

Table of Contents Treatment Guidelines: Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndrome Prognosis of Patients with Acute Coronary Syndrome Risk stratification Elevated Troponin in ACS: Prognostic and treatment implications Prognostic Importance of Elevated CPK-MB Levels Prognostic Value of ST-Segment Depression Importance of “Aspirin Failure” C-Reactive Protein Predicts Risk: Treatment Implications Diabetic Patients: Discordant Benefit Sex-Based Difference in Mortality Age Effects on Mortality Platelet Pathobiology Overview Clinical Trials Overviews of GPIIb/IIIa Trials in Acute Coronary Syndrome Importance of Time to Treatment GP IIb/IIIa Inhibitor Use in Patients Undergoing CABG Combination GPIIb/IIIa Inhibition with Thrombolysis in Acute MI Trials of Oral GPIIb/IIIa Receptor Blockers Editorial Editorial remarks from the authors AUTHORS: Sandip K. Mukherjee, MD, FACC Michael Blum, MD, FACC Last modified: October 14, 1999 (PL) Copyright ©1999 Yale University School of Medicine. All rights reserved. Comments or suggestions to the site editor. Home URL: http://info.med.yale.edu/ysm